Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide

European Journal of Cancer

Volumn 35, Issue 8, 1999, Pages 1258-1263

  Zhang, T C ^a   Cao, E H ^a   Li, J F ^a   Ma, W ^a   Qin, J F ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Apoptosis; As2O3; Intracellular Ca2+; MGC 803 cell

Indexed keywords

ARSENIC TRIOXIDE; CALCIUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CALCIUM; CELL DIVISION; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; OXIDES; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032773828     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00106-9     Document Type: Article

References (20)

1. Huang S.L., Guo A.X., Xiang Y.et al. Clinical study on the treatment of APL mainly with composite Indigo Naturalis tablets. Chin J. Hematol. 16:1995;26-29.
2. Sun H.D., Ma L., Hu H.X., Zhang T.D. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin, J, Integrate Chin. West. Med. 12:1992;170-171.
3. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics. Blood. 89:1997;3354-3360.
4. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood. 88:1996;1052-1061.
5. Tager T. W, Ostrosky-Wegman P. Arsenic: a paradoxical human carcinogen. Mutat Res 1997, 386, 181-184.
6. Bergamaschi G., Rosti V., Danova M., Lucotti C., Cazzola M. Apoptosis: biological and clinical aspects. Haemalologica. 79:1994;86-93.
7. Steller H. Mechanism and genes of suicide. Science. 267:1995;1445-1449.
8. McConkey D.J., Orrenius S. The role of calcium in the regulation of apoptosis. J. Leukoc. Biol. 59:1996;775-783.
9. Mossmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
10. Koken M.H.M., Puvion-Dutilleul F., Guillemin M.C.et al. The t (15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13:1994;1073-1083.
11. Chen Z., Wang Z.Y., Chen S.J. Acute promyelocytic leukemia. cellular and molecular basis of differention and apoptosis Pharmacol. Ther. 76:1997;141-149.
12. Kitamura K., Kiyoi H., Yoshida H.et al. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia clinical and basic studies for the next generation. Cancer Chemother Pharmacol. 40(Suppl.):1997;S36-S41.
13. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
14. Fisher D.E. Apoptosis in cancer therapy. crossing the threshold Cell. 78:1994;539-543.
15. 2+ concentration. Arch. Biochem. Biophys. 269:1989;365-370.
16. Zhu J., Koken M.H.M., Quignon F.et al. Arsenic-induced PML targeting onto nuclear bodies. implications for the treatment ofacute promyelocytic leukemia Proc. Natl. Acad. Sci. USA. 94:1997;3978-3983.
17. 2+ and pH. Biochem. Biophys. Res. Commun. 186:1992;782-789.
18. Alnemri E.S., Litwack G. Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin. J. Biol. Chem. 265:1990;17323-17333.
19. Mass M.J., Wang L. Arsenic alters cytosine methylation patters of the promoter of the tumor suppressor gene P53 in human lung cells. a model for a mechanism of carcinogenesis Mutat Res. 386:1997;263-277.
20. Levine A.T. P53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.